AllianceBernstein’s Soleno Therapeutics SLNO Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | – | Sell |
-43,090
| Closed | -$2M | – | 3422 |
|
|
2026
Q1 | $2M | Buy |
43,090
+800
| +2% | +$31.4K | ﹤0.01% | 2009 |
|
|
2025
Q4 | $1.96M | Hold |
42,290
| – | – | ﹤0.01% | 2018 |
|
|
2025
Q3 | $2.86M | Buy |
42,290
+600
| +1% | +$44.5K | ﹤0.01% | 1799 |
|
|
2025
Q2 | $3.49M | Buy |
41,690
+3,959
| +10% | +$296K | ﹤0.01% | 1651 |
|
|
2025
Q1 | $2.7M | Buy |
37,731
+13,921
| +58% | +$678K | ﹤0.01% | 1741 |
|
|
2024
Q4 | $1.07M | Buy |
23,810
+800
| +3% | +$41.5K | ﹤0.01% | 2305 |
|
|
2024
Q3 | $1.16M | Sell |
23,010
-1,600
| -7% | -$76.6K | ﹤0.01% | 2242 |
|
|
2024
Q2 | $1M | Buy |
+24,610
| New | +$1.04M | ﹤0.01% | 2297 |
|
|
2021
Q2 | – | Sell |
-1,273
| Closed | -$24K | – | 3402 |
|
|
2021
Q1 | $24K | Hold |
1,273
| – | – | ﹤0.01% | 3215 |
|
|
2020
Q4 | $37K | Sell |
1,273
-247
| -16% | -$7.13K | ﹤0.01% | 3152 |
|
|
2020
Q3 | $57K | Sell |
1,520
-787
| -34% | -$23K | ﹤0.01% | 3116 |
|
|
2020
Q2 | $77K | Buy |
+2,307
| New | +$100K | ﹤0.01% | 3128 |
|
AllianceBernstein's SLNO Position: Q2 2026 in Review
AllianceBernstein sold out of Soleno Therapeutics (SLNO) in Q2 2026, closing a stake of 43,090 shares — an estimated $2M sold.
AllianceBernstein first reported a position in SLNO in Q2 2020 and held it in 12 quarters. The position peaked at $3.49M in Q2 2025. 0 funds tracked by Wall St. Rank hold SLNO as of Q2 2026.
- AllianceBernstein reported no remaining Soleno Therapeutics position as of Q2 2026 after selling out during the quarter.
- AllianceBernstein sold 43,090 Soleno Therapeutics shares in Q2 2026, an estimated $2M.
- AllianceBernstein first reported a position in Soleno Therapeutics in Q2 2020 and held it in 12 quarters.
- AllianceBernstein's Soleno Therapeutics position peaked at $3.49M in Q2 2025.
- 0 funds tracked by Wall St. Rank held Soleno Therapeutics as of Q2 2026.
Based on AllianceBernstein's 13F filing for Q2 2026, filed 14 Aug 2026.